《外圍股市》道指期貨續吐17點 納指期貨逆穩
亞太區股市今天個別發展,南韓、台灣及印尼股市續跌0.5%-1%,菲股微吐0.1%;餘下市場均反覆升0.2%-1.1%,中港股市跑贏,深成及滬指高收續升0.8%及1%;港股今天在重磅股騰訊(00700.HK)/美團(03690.HK)/海底撈(06862.HK)續升逾5%-8%支撐反覆兩連升,午後最多漲327點,高見26,610,現報26,566,升282點或1.1%。
美國近日新增確診病例急增,加上市場觀望明天公布通脹數據,美股藍籌指數繼昨晚由紀錄高位回落後,期貨仍反彈乏力,道指期貨報34,981,續吐17點;標普五百期貨報4,424,續吐1點;昨天逆彈納指一百期貨報15,127,反覆續升2點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.